Trial Profile
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms ABLATE
- Sponsors Imunon
- 19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
- 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Feb 2013 Planned number of patients changed from 88 to 41 as reported by ClinicalTrials.gov.